Drug Trial Radar · NCT02815592
Trial of BMS-986012 in Combination With Platinum and Etoposide
Last checked: Nov 19, 2026Latest source record: Sep 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
Nov 28, 2016
Primary completion
Dec 15, 2019
Study completion Aug 6, 2024
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Jun 28, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this this study is to administer BMS-986012 in Combination with Platinum and Etoposide as First-line Therapy in Extensive Small Cell Lung Cancer.
Conditions
- Small Cell Lung Cancer
Interventions
BMS-986012Drug
CisplatinDrug
EtoposideDrug
PlatinumDrug
CarboplatinDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events (AEs)Time frame: Cycle 1, Day 1 up to approximately 26 months.
- Number of participants with serious adverse events (SAEs )Time frame: Date of enrollment up to approximately 26 months.
- Discontinuations due to AEsTime frame: Cycle 1, Day 1 up to approximately 26 months.
- Number of participants who died due to AEsTime frame: Cycle 1, Day 1 up to approximately 26 months.
- Number of participants with laboratory toxicity grade shift from baselineTime frame: Cycle 1, Day 1 up to approximately 26 months.
- Progression Free SurvivalTime frame: From date of first dose or randomization until date of confirmed disease progression, up to 2 years
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Local Institution - 0002
Barcelona, Spain
Local Institution - 0004
Madrid, Spain
Local Institution - 0003
Majadahonda - Madrid, Spain
Local Institution - 0010
Málaga, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.